Zantac Cancer Lawsuits: A Closer Look

  • March 4, 2024

Zantac, the popular antacid drug, has been the subject of multiple lawsuits in recent years. Our goal today is to shed light on the Zantac cancer lawsuits to provide you with essential awareness.

Why is Zantac at The Centre of Lawsuits?

Zantac (ranitidine) was first introduced in 1981 to treat conditions related to the stomach, esophagus, and intestines. Things started to turn south in 2019 when low levels of N-Nitrosodimethylamine (NDMA), a probable carcinogen, were detected in the drug by an online pharmacy.

FDA on Zantac

After several tests, in April 2020, the FDA requested the withdrawal of all Zantac and generic ranitidine products from the market, citing concerns over the NDMA’s potential to cause cancer.

The Connection between Zantac and Cancer

NDMA is classified as a probable carcinogen. Exposure to high levels of NDMA can lead to various types of cancers including stomach, esophageal, colorectal, and liver cancer. The usage of Zantac could have led to prolonged exposure.

Current Status of Zantac Lawsuits

Zantac lawsuits claim that the drug’s manufacturers were aware of the cancer-causing NDMA but chose not to disclose this information. Currently, these cases are in various stages of litigation across the country, with many consolidated under multidistrict litigation in Florida.

Seeking Legal Help

If you or a loved one has developed cancer after prolonged Zantac use, it’s essential to seek legal assistance. A lawyer specialized in such cases can help evaluate if you are eligible for a lawsuit.

In Conclusion

The Zantac cancer lawsuits have highlighted the necessity for rigorous drug testing and transparency from drug manufacturers. Consumers impacted by the drug are right to seek justice, and we hope this closer look at Zantac lawsuits has shed light on this vital public health issue.


Press ESC to close